Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a personalized diet help lung cancer patients? new study aims to find out

NCT ID NCT07486947

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is collecting data from 180 lung cancer patients to understand their nutritional and metabolic status. Researchers will analyze factors like genetics and gut bacteria to create a model that can recommend personalized diets. The goal is to improve quality of life and outcomes for patients with malnutrition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to personalized dietary recommendations that improve nutrition and quality of life for lung cancer patients.
What could go wrong
This is an early, observational study that only collects data—it does not test any treatment. The model may not lead to practical solutions or benefit patients directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study aims to include, across the two planned recruitment centers, between 150 and 180 patients with lung cancer (non-small cell and small cell) treated with chemotherapy, immunotherapy, combinations of immunotherapy and biological therapy, patients receiving conservative therapy, without active treatment, or any other type of treatment. The recruitment centers for lung cancer patients are the Infanta Sofía University Hospital (Madrid, Spain) and the University Hospital of Parma (Parma, Italy). The recruitment center for healthy volunteers is IMDEA Nutrition.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria • Study population cohort: Patients of both sexes Patients aged between 18 and 85 years Patients diagnosed with lung cancer (non-small cell and small cell) Patients treated with chemotherapy, immunotherapy, combinations of immunotherapy and biological therapy, patients receiving conservative therapy, without active treatment, or any other type of treatment, according to ESMO and NCCN guidelines for the management of metastatic lung cancer (small cell and non-small cell) • Control population cohort: Volunteers of both sexes Volunteers aged between 18 and 85 years Volunteers free of oncological disease Exclusion Criteria • Study population cohort: Patients with uncontrolled chronic diseases Patients with acute gastrointestinal diseases • Control population cohort: Volunteers with uncontrolled chronic diseases Volunteers with acute gastrointestinal diseases Volunteers who have had any type of oncological condition at any point in their lives Volunteers with diagnosed pulmonary pathology: chronic lung disease, asthma, pulmonary fibrosis, bronchiectasis, interstitial lung disease, recent pneumonia (3-6 months), moderate/severe sleep apnea, latent or previous tuberculosis with sequelae Volunteers with underlying autoimmune diseases: rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis Volunteers with active or chronic infections: HIV, hepatitis B or C, recurrent chronic infections, tuberculosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IMDEA Nutrition

    RECRUITING

    Madrid, Madrid, 28034, Spain

  • Infanta Sofía University Hospital

    RECRUITING

    San Sebastián de los Reyes, Madrid, 28702, Spain

  • University Hospital of Parma

    RECRUITING

    Parma, Parma, 43126, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.